Cargando…

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

BACKGROUND: In this study, we evaluated the possibility that KRAS mutational status might be predictive of oxaliplatin (OXA) efficacy. We also explored the role of excision repair cross complementing group-1 (ERCC-1). METHODS: Ninety anti-epidermal growth factor receptor-naive advanced colorectal ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basso, M, Strippoli, A, Orlandi, A, Martini, M, Calegari, M A, Schinzari, G, Di Salvatore, M, Cenci, T, Cassano, A, Larocca, L M, Barone, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553525/ https://www.ncbi.nlm.nih.gov/pubmed/23175150 http://dx.doi.org/10.1038/bjc.2012.526

Ejemplares similares

ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas
por: Orlandi, A., et al.
Publicado: (2015)

ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis
por: Strippoli, Antonia, et al.
Publicado: (2016)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
por: Jun, H J, et al.
Publicado: (2008)

Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer
por: Vreuls, C P H, et al.
Publicado: (2013)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study
por: Horsch, M, et al.
Publicado: (2009)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
por: Hamidi, H, et al.
Publicado: (2014)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
por: Gonzalez de Castro, D, et al.
Publicado: (2012)

PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients
por: Harwood, C A, et al.
Publicado: (2008)

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
por: Elsheikh, S E, et al.
Publicado: (2008)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives
por: Janjetovic, Z, et al.
Publicado: (2011)

Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas
por: Ivanov, S V, et al.
Publicado: (2013)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
por: Sunaga, N, et al.
Publicado: (2014)

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
por: Calegari, M A, et al.
Publicado: (2017)

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
por: Matsubara, J, et al.
Publicado: (2008)

TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome
por: Journe, F, et al.
Publicado: (2011)

β(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients
por: Shrout, J, et al.
Publicado: (2008)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers
por: Sung, Hyuna, et al.
Publicado: (2016)

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
por: van Grieken, N C T, et al.
Publicado: (2013)

Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer
por: Hamaya, Y, et al.
Publicado: (2010)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer
por: Ohlsson, L, et al.
Publicado: (2012)

Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
por: Sternemalm, J, et al.
Publicado: (2014)

mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete
por: Yannopoulos, A, et al.
Publicado: (2005)

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vecude5vgu6cbf4tm0gvafov6b